Adam Dolder

NEW YORK, April 30, 2024 /PRNewswire/ -- PRISM Consulting Partners, a Florida based healthcare private practice acquisition advisory and consulting company, and Lion Management Services Organization of New York, have partnered to form PRISM Concierge. PRISM Consulting Partners was formed in 2023 by founders Michael Guelcher, David Molle, and Brian Whitman. The three partners have over 60 years combined experience in acquisitions, transitioning practices, and healthcare business development. Lion Management was founded in 2021 by James Vena, a Wall Street veteran with 35 years of value creation and capital investment experience. Lion Management implements and manages strategic solutions for private healthcare practices. The newly formed PRISM Concierge aims to be a full-service provider to private healthcare practitioners looking for options ranging from maximizing profit to ultimately transitioning to their desired outcome. The client receives management of back-office services tailored to achieve that outcome. "PRISM Concierge offers the mechanisms and resources to achieve a higher level of freedom," states Michael Guelcher, PRISM Partner. "Change readiness encompasses discipline now, for more freedom and greater rewards later." David Molle goes on to state, "We're filling a void in the healthcare market by bringing together shared resources and services that will ultimately improve a practice's bottom line, while freeing up time to allow for better patient care. Essentially, we're doing the things Drs. don't get paid to do. From shared billing and credentialling, to consultants, attorneys, IT, HR, and a complete group purchasing organization to name a few, your "concierge" can help with most aspects of your business as a single point of contact." James Vena, CEO, Lion Management is enthused about the impact PRISM Concierge can have in the marketplace. "Our recent success of organizing a group of 20 practices in a short window and making them the 35th largest eyecare practice in just two years translates well. We are embarking on something that has never been done before, and there is considerable demand for these services." About PRISM Consulting: https://lnkd.in/ed3gHdVd About Lion Management Services https://lnkd.in/ei-cpseE https://lnkd.in/ei-cpseE #eyecare #privateequity #healthcare #eyewear #optometrist #exits #mso #managementservices

10

4 Comments

The healthcare landscape is rapidly evolving, driven by advancements in technology and a deeper understanding of patient care. I had the pleasure of speaking with Ambar Bhattacharyya, Co-Managing Partner at Maverick Ventures, on the latest episode of The Full Ratchet. Ambar has partnered with numerous billion-dollar companies like hims & hers, Cityblock Health, Devoted Health, and ConcertAI. His unique journey from rural America to becoming a prominent figure in venture capital offers invaluable insights into the future of healthcare and technology. We discuss his investment strategy at Maverick Ventures, the megatrends shaping healthcare, the impact of AI on the industry, and the importance of integrated care. Ambar also shares his thoughts on the challenges and opportunities in healthcare investment, offering a comprehensive view of what lies ahead. Check out TFR Episode 438 to catch our conversation. You'll be glad you listened.

117

8 Comments

It was great to be back in Boston last week, reconnecting with returning Institute members and meeting new market and investment leaders! We are excited for the events and research areas we have coming up in the next few months! #ocio #investmentsolutions #investmentmanagement #investmentconsulting

8

We look forward to supporting Asceneuron SA’s seasoned management team as they advance ASN 51, a highly promising oral OGA inhibitor into Phase2 testing for Alzheimer’s disease. This sizeable and oversubscribed financing alongside top-tier investors, led by Novo Holdings, is a testament to the high quality of the opportunity. It throws a spotlight on an exciting novel oral compound class of OGA inhibitors targeting a key disease driver protein: Tau, particularly intracellularly, where the vast majority of Tau associated pathology resides in Alzheimer’s disease. The potential for success in Phase 2 of this novel class of oral agents offers the promise to help significantly advance the Alzheimer’s field, currently dominated by anti-amyloid injectable drugs. With this latest biotech deal in Switzerland, the Novo Holdings Venture Investments team is continuing its mission to identify and invest in the most innovative and exciting European and US biotech companies which can help to truly advance patient care. Magne Stoknes Principal, joins me on the Board of Asceneuron as Board Observer. #NovoHoldings #Alzheimer’s #Swissbiotech #CNS #Neurodegeneration #Europeanlifesiences #venturecapital

76

2 Comments

Healthcare Innovation and Investment News for the week from HDIG HDIG Search, Consulting and Venture HDIG is an ecosystem with a searchable database of hospital healthcare venture, innovation centers, tech transfer offices and their portfolio companies. It would assist you in understanding the landscape of partnerships, performance, and contacts. Early-stage companies use it to find partners and funding for their pilots, or even professional firms or tech companies depending on their needs. Launched this year with nearly 10,000 companies, hospitals, and funds, get full access for a special monthly subscription of only $100 and you can cancel at anytime, this would include building your profile. Learn more about our Acceleration Pilot Program, paid pilots, reverse studio model and other research and services. #HDIG #HealthcareInnovation #HealthcareVenture #HospitalInnovation

3

Boards of Directors – How Relevant To The Business Is The Board? In 2014, activist investor Starboard Value successfully replaced all 12 directors on the board of Darden Restaurants. The following shows the Darden incumbent board at the time of Starboard's proxy fight, Starboard’s value creation plan initiatives, the Starboard director nominees and the before and after performance (revenue, EBITDA, EBITDA margin and stock price). Note especially the direct relevance of each Starboard nominee to the industry or some aspect of the value creation plan. How often do you see this level of relevance on public company boards?

11

13 Comments

Looking back at the past 30 years, I remember myself doing science about 55-60 hours a week, and then helping venture capitalists and biotech start-ups about 70-80 h/week. Usually unsatisfied, sometimes exhausted, but pleased overall. This overexciting workaholism was somehow interrupted last year. I had less work and a lot of mountaineering, - climbed about 5.5 Chomolungma attitudes during the year. It feels like I have reached the stage at which it is a time to start sharing experiences and understanding of the universe. This week, I started to share by publishing an analytic report at SeekigAlpha about TG Therapeutics. This small biotech company has developed a third-to-market anti-CD20 mAb for the treatment of multiple sclerosis (MS). Along with the company, this report briefly touches upon current treatments for MS, the competitive landscape of therapeutics, and the uncertainties surrounding the development of new BTK inhibitors. https://lnkd.in/drAFx9vt

10

Last week, Virginia Li at FirstWord Group led a fantastic discussion of the biotech markets with my public perspectives and the venture financing perspectives of Colleen Feriod Cuffaro of Canaan. A recording of our panel is available at the link below. Takeaways: * We are seeing a pick up in financing volumes but the bar for quality is still very high. It is a also longer process to get through a successful financing, but take the money if you can get it. Dilution is secondary to having a strong syndicate and runway. * Hot areas of investor focus are oncology and autoimmunity. The flavor de jour is applying traditional oncology drugs such as cell therapy and bispecifics to autoimmunity! We have seen early data in myasthenia gravis and lupus. * Gene therapy appears to have cooled off with increasing competition for treating the same disease areas with different modalities such as siRNA. https://lnkd.in/gdtmGDBY

44

1 Comment

A series for those interested in listening to transformational healthcare

2

Our partner Eddie Eltoukhy has identified these opportunities in Biotech. Eddie has a PhD in bioengineering from Massachusetts Institute of Technology and over a decade experience as an operator. Reach out to him if you are working on these areas of biotech. Pear VC - Technology-Driven Therapeutic Platforms Companies developing therapeutic assets with a core product engine Proprietary tool, workflow, or samples leading to novel biological data sets Preference for omics platforms or high throughput screening / engineering workflows First-in-class or best-in-class drugs - Next-Generation Therapeutic Modalities Technologies to improve the efficacy, safety, access, or reach of next-gen modalities including the following: Genomic medicines (gene tx & gene editing) Cell therapies Targeted protein degraders Antibody-drug conjugates Radiopharma - Precision Medicine New technologies supporting the discovery of novel biomarkers and the generation of proprietary data sets for applications in: Disease screening Therapy selection Recurrence monitoring - Life Sciences + AI Software Platforms Software & AI-driven platforms to improve all aspects of life sciences R&D, including: Target discovery and validation Drug design and optimization Manufacturing Regulatory Clinical development

120

5 Comments

This week Mikal Ventures brings you a 4-week breakdown of the US capital market with an emphasis on the Mikal verticals. Over the 4-week period ending April 15, just over 900 new companies were added, with 94,109 companies included in the US Health Tech, Med Tech, Fin Tech, AI Tech, and Ed Tech verticals. AI Tech again saw the greatest percentage of growth in new companies and transactions, weighing in at over double the vertical averages for the period. The US Fin Tech vertical again led the way in SEC Filings and news articles. Mikal Ventures publishes these stats on a rolling 4-week basis to provide a perspective on how the verticals and new startups move through time. We hope you find them informative and thought-provoking. VC Investors are always adjusting their "Play Book" with a variety of options for investing. Mikal Ventures is one of those alternatives, offering curated solutions to real world problems. Reach out if you have questions on how we can be of assistance and bookmark https://mikalventures.com/ for additional insights and information.

3

3 Comments

the KdT podcast is back to unpack the first biotech IPO of 2024 - CG Oncology. in The World in a Grain of Sand, we break down an S1 from a recent biotech IPO and share insights on the science, business models, and financials. in this episode, Cain McClary, MD and Phil Grayeski discuss CG Oncology, and dive into: - the various subtypes of bladder cancer, and one of the most unique standard of care treatment paradigms in oncology, which utilizes a live attenuated virus to treat the disease - supply chain and manufacturing issues that have limited access to SoC therapy in bladder cancer - CG Oncology’s lead (and only) asset, an oncolytic immunotherapy which has delivered impressive complete response data in bladder cancer - challenges and open questions around complex manufacturing, clinical and commercial adoption, and competition for CG’s product - bull vs bear case for the company link to the full episode in the comments.

59

1 Comment

Sharecare (NASD: SHCR) is the recent target of Altaris as more public companies are going private in the current difficult capital markets environment. Other deals include clinical trials, mental health and more. Read the latest deal news in LECOs weekly healthcare newsletter. PitchBook also released their takeaways from the Healthcare Capital Markets & Innovation Summit LLC HCMIS24 (Save the date May 28-29 2025) #healthcareinnovation #dealmaking #privateequity #goprivate #TheSmartHealthCity #HCMIS #HCMIS25

5

As I said right at the start of this week's The Heart of Healthcare Podcast, Shivdev Rao is one of the most exceptional founders I have ever worked with. He is also a great human being. In this week's episode he shares what is it like leading the 🚀 that is Abridge and some awesome life lessons. IMHO this is a great listen for founders building in both the AI and healthcare fields!

57

3 Comments

This will be a fascinating SynBioBeta talk - on how the combined tools of synthetic biology allowed Creyon Bio to build a successful drug in a few months 😳

13

From the article: Our research has shown that modest weight reduction due to caloric restriction to about 1,200 calories a day leads to a reduction of liver fat and reversal of liver insulin resistance and type 2 diabetes. You don’t have to get down to the weight you were in high school—a 10% weight reduction can make a big difference. This is also likely the major mechanism by which the new GLP-1 agonist medications are working to reverse type 2 diabetes. We have also learned that exercise opens the door for glucose transport into the muscle cell, bypassing the block in insulin action. If you have muscle insulin resistance, you can normalize the storage of ingested carbohydrate into the muscle as glycogen, decreasing the conversion of carbohydrate to fat in the liver. This, in turn, leads to protection from the development of fatty liver disease and improvement in the plasma lipid profile, which will protect against the development of atherosclerosis. I encourage my patients with diabetes or prediabetes to find a physical activity they like to do every day and stick with it. As we deepen our understanding of the molecular basis of insulin resistance and develop new drugs to target this mechanism, I’m optimistic about the future of treating insulin resistance and improving cardiometabolic health.

5